Search results
Results from the WOW.Com Content Network
Lipodystrophy syndromes are a group of genetic or acquired disorders in which the body is unable to produce and maintain healthy fat tissue. [ 1 ] [ 2 ] The medical condition is characterized by abnormal or degenerative conditions of the body's adipose tissue .
Small cell lung cancer has a five-year survival rate of 4% according to Cancer Centers of America's Website. [5] The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer.
Cancer mortality rates are determined by the relationship of a population's health and lifestyle with their healthcare system. In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [ 1 ]
Familial partial lipodystrophy, also known as Köbberling–Dunnigan syndrome, [2] is a rare genetic metabolic condition characterized by the loss of subcutaneous fat. [ 3 ] : 495 FPL also refers to a rare metabolic condition in which there is a loss of subcutaneous fat in the arms, legs and lower torso.
Patients reported improved quality of life and reduced need for other medications without significant adverse effects. [ 9 ] One research published in 2017 reported a middle-aged patient developed AGL after treatment and recovery for autoimmune thrombocytopenia that included immunoglobulin therapy and prednisone, [ 17 ] which suggests the ...
While the disease is fatal, the age of onset is a key factor, as infants have a typical life expectancy of 2–8 years, while adults typically live more than a decade after onset. Treatment options are limited, although hematopoietic stem cell transplantations using bone marrow or cord blood seem to help in certain leukodystrophy types, while ...
Congenital generalized lipodystrophy, also known as Berardinelli–Seip lipodystrophy was first described in 1954 by Berardinelli [18] and later by Seip in 1959. [19] The gene for type 1 CGL was identified as AGPAT2 at chromosome 9q34, [ 20 ] and later the gene for type 2 CGL was identified as BSCL2 at chromosome 11q13. [ 21 ]
Marfanoid–progeroid–lipodystrophy syndrome (MPL), also referred to as Marfan lipodystrophy syndrome (MFLS), is a variant of MFS in which Marfan symptoms are accompanied by features usually associated with neonatal progeroid syndrome (also referred to as Wiedemann–Rautenstrauch syndrome) in which the levels of white adipose tissue are ...